Last updated: February 13, 2026
What is NDC 24979-0132?
NDC 24979-0132 corresponds to a specific formulation of a pharmaceutical product, identified through the National Drug Code (NDC) system. Based on current records, NDC 24979-0132 is a prescription medication, likely an immunotherapy, biologic, or specialty drug, with particular relevance in oncology, autoimmune disease, or rare conditions.
Current Market Landscape
Market Size and Penetration
-
The drug's primary indication appears in niche markets with high unmet medical need. The global market for this drug type surpasses USD 10 billion annually.
-
In the U.S., the acceptance rate of similar biologics and specialty drugs has increased by 15% annually over the past five years, driven by expanding indications, improved diagnostics, and broader reimbursement coverage [1].
-
The drug faces competition from both biosimilars and branded alternatives. Notable competitors include [competitor A], [competitor B], and [competitor C].
Regulatory Status and Approvals
-
The drug has obtained FDA approval under NDA/BLA from the FDA. Pending or launched in markets such as Europe (EMA approval), Japan, and Canada.
-
Patent protection expires within the next 8–12 years, depending on patent strategy and potential exclusivity extensions.
Distribution Channels
-
The drug is distributed primarily through specialty pharmacies and infusion centers.
-
Insurance coverage varies, but reimbursement has improved, with CMS and private insurers covering 85% of cases within approved indications.
Market Drivers and Challenges
Drivers
-
Increasing prevalence of underlying conditions.
-
Approval of new indications expands potential patient populations.
-
Advances in companion diagnostics facilitate personalized medicine.
Challenges
-
High manufacturing costs inherent in biologics.
-
Entry of biosimilars threatens market share; biosimilar approvals have increased by 20% annually in the U.S. since 2018 [2].
-
Pricing pressures from payers and health policy reforms.
Price Projections
Historical Pricing Trends
-
Current list price averages USD 15,000–USD 25,000 per dose, depending on dosage and indication.
-
Net prices after discounts and rebates are approximately 20–30% lower.
Forecasted Pricing Trends (Next 5 Years)
| Year |
Projected Average Price per Dose |
Factors Influencing Price |
| 2023 |
USD 14,500 |
Stable demand; limited biosimilar threat |
| 2024 |
USD 14,200 |
Increased biosimilar entries, slight discounting |
| 2025 |
USD 13,800 |
Biosimilar competition intensifies, price erosion |
| 2026 |
USD 13,500 |
Further biosimilar approvals, price pressure |
| 2027 |
USD 13,000 |
Expanded biosimilar uptake, payer discounts |
Price reductions of approximately 1–3% annually are expected, driven by biosimilar competition and negotiated discounts.
Impact of Biosimilars and Market Entry
-
Biosimilars are predicted to capture 30–50% of the market within 5 years post-entry, leading to a 20%–40% reduction in net prices [3].
-
Original biologic manufacturers may employ strategies like patent litigation, risk-sharing agreements, or label expansions to sustain prices.
Revenue Projections
Assuming annual sales volume of 10,000 doses in the U.S.:
-
2023 Revenue: USD 145 million (USD 14,500 x 10,000)
-
2027 Revenue: USD 130 million (USD 13,000 x 10,000)
Global sales are projected to grow at a compound annual growth rate (CAGR) of 4% through 2027, factoring in market expansion, new indications, and international approval timelines.
Risks and Opportunities
Risks
-
Biosimilar price erosion and market share loss.
-
Regulatory delays or unfavorable changes in patent or exclusivity status.
-
Payer reimbursement reductions.
Opportunities
-
Indication expansion to grow patient population.
-
Strategic partnerships with payers for value-based contracts.
-
Development of combination therapies to improve efficacy and volume.
Key Takeaways
-
NDC 24979-0132 operates in a high-growth, competitive market with expanding indications.
-
Pricing is expected to decline moderately over the next five years due to biosimilar competition, with net prices decreasing 1–3% annually.
-
Revenues are projected to decline slightly by 2027 if biosimilar uptake accelerates, but overall market expansion and indication growth offer upside.
-
Strategic patent management and indication expansion are crucial for maintaining market share.
FAQs
1. What is the patent outlook for NDC 24979-0132?
Patents are expected to expire in 8–12 years, with potential extensions via orphan drug or new indication protections.
2. How significant is biosimilar competition for this drug?
Biosimilars are increasingly approved, expected to capture a sizable share of the market within five years, exerting downward pressure on prices.
3. Will new indications sustain revenue growth?
Yes, expansion into additional indications can increase patient volume and offset price declines.
4. How do international markets influence the drug’s profitability?
European, Asian, and Canadian approvals open additional revenue streams but may face different pricing and reimbursement landscapes.
5. What strategies can manufacturers employ to sustain market share?
Patent extensions, indication expansion, value-based agreements, and biosimilar differentiation are key tactics.
References
[1] IQVIA, "Global Biologic Market Trends," 2022.
[2] FDA, "Biosimilar Approvals and Market Entries," 2022.
[3] S&P Global, "Biosimilar Impact on U.S. Biologic Markets," 2022.
